Loading…
Calidi Biotherapeutics, Inc. is projected to rise to $1.79 by 2027, a +7% move from its current price of $1.68. CLDI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.52 | $1.68 | $1.86 | -0.01% |
| Aug 6 | $1.45 | $1.68 | $1.94 | -0.01% |
| Aug 7 | $1.41 | $1.68 | $2.01 | -0.02% |
| Aug 8 | $1.37 | $1.68 | $2.06 | -0.02% |
| Aug 9 | $1.34 | $1.68 | $2.11 | -0.03% |
| Aug 10 | $1.31 | $1.68 | $2.16 | -0.04% |
| Aug 11 | $1.28 | $1.68 | $2.20 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.28 | $1.68 | $2.20 | -0.04% |
| Week 2 | $1.14 | $1.68 | $2.46 | -0.08% |
| Week 3 | $1.05 | $1.68 | $2.68 | -0.13% |
| Week 4 | $0.975 | $1.68 | $2.89 | -0.17% |
| Week 5 | $0.9141 | $1.68 | $3.07 | -0.21% |
| Week 6 | $0.8623 | $1.68 | $3.26 | -0.25% |
| Week 7 | $0.8173 | $1.68 | $3.43 | -0.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Calidi Biotherapeutics, Inc. is a biotechnology company focused on developing targeted therapies to deliver genetic medicines to distal sites of disease. The company operates in the Healthcare sector and advances a portfolio that includes CLD-101, CLD-201 and CLD-401 programs, as well as oncolytic virus platforms NeuroNova and SuperNova.
Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Calidi Biotherapeutics, Inc. (CLDI) is currently trading at $1.64, with a market capitalization of $1.98M and a ranking of 5441 by market cap. The stock trades in a volatile niche within healthcare biotech and shows a price level that aligns with a micro-cap profile.
The 30-day technical backdrop shows a neutral to cautious setup, while the forecast provides a path of potential upside over the coming years. The stock carries higher-than-average volatility, with annualized volatility listed at 100%. The year-by-year forecast suggests an evolving bullish outlook in the later years, with the average price rising from the current level toward multi-dollar targets by 2050.
A major floor 94.5% below — a decisive break under it would weaken the trend.
The nearest floor, 94.0% below — buyers have tended to step in here.
The nearest ceiling, 4.8% above — a clean break opens room to run.
A major ceiling 62.2% above — clearing it would confirm fresh momentum.
Key CLDI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLDI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7019 | Buy | $0.8031 | Buy |
| MA 10 | $0.4055 | Buy | $0.5558 | Buy |
| MA 20 | $0.2713 | Buy | $0.3773 | Buy |
| MA 50 | $0.2104 | Buy | $0.2747 | Buy |
| MA 100 | $0.2326 | Buy | $0.4046 | Buy |
| MA 200 | $0.727 | Buy | $2.56 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.33 | Neutral |
| Stoch RSI (14) | 54.10 | Neutral |
| CCI (20) | 304.50 | Buy |
| Williams %R (14) | -14.17 | Info |
| MACD (12,26,9) | 0.12 | Buy |
| ROC (12) | 1119.67 | Buy |
| Bollinger %B (20,2) | 1.18 | Sell |
| Stochastic %K (14) | 85.83 | Sell |
| TRIX (15) | 4.24 | Buy |
| Awesome (5,34) | 0.48 | Buy |
| Ultimate (7,14,28) | 64.59 | Neutral |
| Momentum (10) | 1.37 | Buy |
| Aroon Osc (25) | -4.00 | Sell |
| Hull MA (9) | 1.10 | Buy |
| ADX (14) | 32.56 | Buy |
| ATR (14) | 0.31 | Info |
The near-term technical picture is NEUTRAL. RSI14 is 30, indicating a relatively oversold condition, which can accompany limited upside momentum in the immediate term.
The 30-day range spans $1.15 to $2.35, with a SMA50 of $0.1521 and a SMA200 of $0.7193. Support is listed at $0.093 and resistance at $0.17, framing a narrow band around the current price. The combination of these indicators points to a cautious stance in the near term while the stock remains susceptible to volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.10 | $1.68 | $2.01 | 0% | Neutral | |
| $1.30 | $1.79 | $2.66 | +7% | Neutral | |
| $1.31 | $1.91 | $3.02 | +14% | Neutral | |
| $1.50 | $2.31 | $3.84 | +37% | Bullish | |
| $1.56 | $2.51 | $4.35 | +49% | Bullish | |
| $1.25 | $2.11 | $3.79 | +26% | Bullish | |
| $1.11 | $1.94 | $3.59 | +16% | Neutral | |
| $1.02 | $1.86 | $3.54 | +11% | Neutral | |
| $1.08 | $2.06 | $4.02 | +23% | Bullish | |
| $1.35 | $2.68 | $5.34 | +59% | Bullish | |
| $1.16 | $2.59 | $5.67 | +54% | Bullish | |
| $2.73 | $6.07 | $13.95 | +261% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.10 | $1.68 | $1.90 | +0.00% |
| September 2026 | $1.29 | $1.57 | $1.99 | -6.76% |
| October 2026 | $1.36 | $1.67 | $2.16 | +6.66% |
| November 2026 | $1.28 | $1.60 | $2.10 | -4.50% |
| December 2026 | $1.19 | $1.50 | $2.01 | -5.72% |
Click any year to see its month-by-month CLDI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Calidi Biotherapeutics, Inc.'s 2026 outlook centres on $1.68, within a $0.10 to $2.01 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CLDI could reach as high as $2.66, with a base case around $1.79 and support toward $1.30 — roughly +7% from $1.68. Price action looks broadly range-bound.
Expect CLDI to range from $1.31 to $3.02 through 2028. The $1.91 average target implies a +14% move from current prices. That is up +7% on the projected 2027 average. A consolidation phase looks the most probable path here.
The CLDI price prediction for 2029 points to an average of $2.31 (low $1.50, high $3.84) — a potential gain of +37% on today's $1.68. Momentum favours further upside here.
In 2030, CLDI is projected to trade between $1.56 and $4.35, averaging $2.51 — a potential gain of +49% from today's $1.68. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Calidi Biotherapeutics, Inc.'s 2031 outlook centres on $2.11, within a $1.25 to $3.79 range. That is -16% versus the projected 2030 average. That marks a +26% change versus current levels. Momentum favours further upside here.
By 2032, CLDI could reach as high as $3.59, with a base case around $1.94 and support toward $1.11 — roughly +16% from $1.68. A consolidation phase looks the most probable path here.
Expect CLDI to range from $1.02 to $3.54 through 2033. The $1.86 average target implies a +11% move from current prices. That is -4% versus the projected 2032 average. Price action looks broadly range-bound.
The CLDI price prediction for 2034 points to an average of $2.06 (low $1.08, high $4.02) — a potential gain of +23% on today's $1.68. Buyers look set to stay in control over this stretch.
In 2035, CLDI is projected to trade between $1.35 and $5.34, averaging $2.68 — a potential gain of +59% from today's $1.68. That is up +30% on the projected 2034 average. Momentum favours further upside here.
Calidi Biotherapeutics, Inc.'s 2040 outlook centres on $2.59, within a $1.16 to $5.67 range. That is -3% versus the projected 2035 average. That marks a +54% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CLDI could reach as high as $13.95, with a base case around $6.07 and support toward $2.73 — roughly +261% from $1.68. Momentum favours further upside here.
Investing $1,000 in CLDI today (≈ 595.238095 CLDI) could be worth
$3,611.35
+$2,611.35 (+261%) by 2050 · US Dollar
Based on the average projected CLDI price of $6.07 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLDIwould be worth at today's price.
$1,000 invested in CLDI on Jul 30, 2025 (≈ 142.450143 CLDI) would be worth
$239.32
-$760.68 (-76.1%) today · 0.24× · US Dollar
Based on a CLDI entry price of $7.02 vs. today's $1.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.105 | $16,000 | +1500.0% |
| 1 month ago | $0.17 | $9,882.35 | +888.2% |
| 3 months ago | $0.216 | $7,777.78 | +677.8% |
| 6 months ago | $1.02 | $1,647.06 | +64.7% |
| 1 year ago | $7.02 | $239.32 | -76.1% |
| All time (4.7y) ago | $1,173.6 | $1.43 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLDI forecast.
Our base-case forecast reaches $3.40 around 2050.
Implied market cap at $3.40: $4.1M
The multi-year forecast projects a bullish tilt beginning in the latter part of the decade and extending through 2050. For 2030 the forecast shows a min of $1.50, an avg of $2.43 and a max of $4.20, with a 48% ROI and a BULLISH sentiment. By 2040, the forecast envisions a min of $1.14, an avg of $2.52 and a max of $5.53, with a 53.9% ROI and BULLISH sentiment.
By 2050, the forecast calls for a min of $2.64, an avg of $5.87 and a max of $13.50, with a 257.8% ROI and a BULLISH sentiment.
Overall, the projections suggest meaningful upside potential over the long term, albeit with considerable uncertainty inherent to biotech equities. These are estimates and not guarantees, and actual results will depend on development progress, regulatory outcomes, and market factors.
Tap a question to reveal the answer.
2030 min $1.50, avg $2.43, max $4.20; ROI 48; sentiment BULLISH.
Forecast data show neutral to cautious signals in 2026 with current price alignment, followed by bullish sentiment in 2029–2050. The 2030 avg is $2.43 with a max of $4.20 and 2050 avg is $5.87 with a max of $13.50, reflecting upside potential but not a guarantee.
The 2035 forecast lists a min of $1.31, avg $2.60, max $5.18 with ROI 58.4 and BULLISH sentiment; the 2040 forecast shows a max of $5.53, suggesting $5 could be approached or exceeded in that window, but these are not guarantees.
Current price is $1.64 and market cap is $1.98M.
RSI14 is 30; 30-day range is $1.15 to $2.35; SMA50 is $0.1521; SMA200 is $0.7193; support is $0.093 and resistance is $0.17.
Calidi Biotherapeutics, Inc. Community Discussion
0Share your Calidi Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.